{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:13:36Z","timestamp":1793978016277,"version":"4.8.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.annder.2013.02.029","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T12:30:43Z","timestamp":1368102643000},"page":"448-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Myosite orbitaire associ\u00e9e \u00e0 un traitement par ipilimumab"],"prefix":"10.1016","volume":"140","author":[{"given":"M.","family":"Lecouflet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Verschoore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Giard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gohier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Milea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2013.02.029_bib0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.029_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","article-title":"Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer","volume":"65","author":"Graziani","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.annder.2013.02.029_bib0015","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4\u00a0blockade in patients with metastatic melanoma","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.02.029_bib0020","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.029_bib0025","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.029_bib0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4\u00a0blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"10.1016\/j.annder.2013.02.029_bib0035","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2013.02.029_bib0040","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4\u00a0blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2013.02.029_bib0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7525-10-66","article-title":"Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment","volume":"10","author":"Revicki","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annder.2013.02.029_bib0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4\u00a0blockade in patients with metastatic melanoma: a new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.annder.2013.02.029_bib0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813007205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813007205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:45Z","timestamp":1758970845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963813007205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":11,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0151963813007205"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2013.02.029","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myosite orbitaire associ\u00e9e \u00e0 un traitement par ipilimumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2013.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}